Hormonal

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

StrongSupportsmedium confidence

Patients with a longer duration of GLP-1RA treatment (OR = 1.014, 95% CI, 1.008-1.019) and higher HOMA-β levels (OR = 4.912, 95% CI, 1.480 to 16.034) were more likely to achieve successful weight reduction at follow-up of 12 months.

Jingxuan Wang et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on a retrospective cohort study with a substantial sample size.

Source

Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity

Jingxuan Wang et al. · Diabetes Obesity and Metabolism · 2025

cohort · n=679Cited 2×

Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →